HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination therapy

Written by Petra Hegmann on 20th October 2021. Posted in Client News.

• Previous
• Next